You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Appointments
Find a Doctor
Contact Us
Menu
About SingHealth
Back to Home
Corporate Profile
About Us
Our Leadership
Whistle-blowing Policy
Eastern General Hospital
Regional Health System
About Us
Keep Well
Get Well
Live Well
Get Involved
SingHealth Community Hospitals
SingHealth Polyclinics
Global Health
SingHealth Duke-NUS
Global Health Institute
International Collaborations
Newsroom
Press Releases
News Articles
Annual Reports
Singapore Health
Defining Med
Publications
Tomorrow's Medicine
Faces of Healthcare
Procurement
About Us
Business with GPO
Events
GPO Pharmaceutical
GPO Non-Pharmaceutical
Contact Us
Contact Us
Feedback
Our Locations
Check Fake News
Patient Care
Back to Home
Conditions & Treatments
Conditions & Treatments
Medicine
Patient Education
Specialties & Services
SingHealth Duke-NUS Disease Centres
Sub-Specialty Centres & Services
Clinical Specialties
Clinical Outcomes
SingHealth Duke-NUS Transplant Centre
Find A Doctor
HealthXchange
Patient & Visitor Info
Your Clinic Visit
Your Ward Stay
Appointments
Fees & Charges
Payments
Visitor Guide
Events
Find a GP Clinic
Health Buddy
e-Services
Make/Change/Cancel Appointment
Pay Online
Medicines Order Service
X-ray Queue Watch
Health Buddy
Feedback
Research & Innovation
Back to Home
Academic Medicine Research Institute (AMRI)
Our Researchers
Grant Calendar
iSHaRe
Academic Medicine Innovation Institute (AMII)
Education & Training
Careers
Back to Home
Why Choose Us
Our Culture
Learning & Development
Talent Recognition & Retention
Career Choices
Doctors
Nurses
Allied Health Professionals
Management and Administration
Research
Ancillary and Support
Scholarships
Scholarships Overview
Be an Allied Health Scholar
Be a Nursing Scholar
Sponsorships
Sponsorships Overview
Allied Health Sponsorship
Nursing Sponsorship
Job Opportunities
Contact Us
Giving
Back to Home
Why Give
Finding a Cure
Advancing Medical Education
Helping our Patients
Appreciating your support
Furthering Donor Impact
Get Involved
Make a Gift
Leave a Legacy
Become a Corporate Donor
Create a Named Fund
Your Gift at Work
Meet Grateful Patients
Meet Donors like You
Meet Our Researchers
Meet Our Educators
Be Informed
Inspire
Giving News
Make a Gift
Home
to skip to the main content on a page
to skip to the main content on a page
Home
>
Pages
>
Category Common Content Tags0513 3488.aspx
Page Content
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Bronchiectasis
Phase II Trial on using new drug for targeted Bronchiectasis therapy.
Kidney Disease (Membranous Nephropathy)
The purpose of the study is to find out if the drug called “LNP023” is safe and has beneficial effects in people who have membranous nephropathy (MN) compared with rituximab. MN is a disease of the kidney that causes an increase in the amount of protein eliminated in the urine. The main objective of this research is to see whether taking LNP023 or rituximab for 6 months results in lower urine protein levels and to compare these two treatments in patients with MN.
Breast Cancer
HER2-, Hormone Receptor +, Advanced Breast Ca
×
SUBSCRIBE TO HEALTHXCHANGE
Subscribe to our mailing list to get the updates to your inbox
Find a Doctor
Conditions & Treatments
Home
Appointments
e-Services
